Results 91 to 100 of about 3,500 (175)

Considerations regarding an updated meta-analysis of the optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer. [PDF]

Int J Surg
Pang H, Yan M, Chen L, Zhao Z, Li W, Zhang S, Sun H.   +6 more
europepmc   +1 more source

Competitive LC-MS/MS assay to investigate protein metalation dynamics.

Inorg Chem Front
Küssner K, Wolf M, Cucchiaro A, Hartinger CG, Meier-Menches S, Cziferszky M.   +5 more
europepmc   +1 more source

First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial. [PDF]

Nat Commun
Lorenzen S, Goetze TO, Thuss-Patience PC, Riera-Knorrenschild J, Goekkurt E, Dechow TN, Ettrich TJ, Hofheinz RD, Luley KB, Pink D, Lindig U, Folprecht G, Schuch G, Bitzer M, Heinemann V, Angermeier S, Bolling C, Loose M, Junge S, Pauligk C, Al-Batran SE.   +20 more
europepmc   +1 more source

Targeting FBXL5 to induce ferroptosis and reverse oxaliplatin resistance in iron-rich colorectal cancer. [PDF]

Sci Rep
Wang M, Zhang R, He S, Wen F, Yu X, Xu X, Li Y, Wu S.   +7 more
europepmc   +1 more source

A Targeted Redox-Active Dual-Action Pt(IV)-Mn(II) Prodrug Displays Enhanced In Vivo Anticancer Activity. [PDF]

Adv Healthc Mater
Lopez-Sanchez A, Chédotal H, Muthuramalingam RPK, Thomas M, Yau JNN, Sahoo PR, Policar C, Batteux F, Medjoubi K, Somogyi A, Adriani G, Nicco C, Coriat R, Pastorin G, Bertrand HC.   +14 more
europepmc   +1 more source

Locoregional and systemic control after total neoadjuvant therapy with short-course radiotherapy for locally advanced rectal cancer: long-term outcomes from the LARCT-US study. [PDF]

Br J Surg
Imam I, Nilsson PJ, Khan T, Angenete E, Glimelius B.   +4 more
europepmc   +1 more source

Multi-Kinase Inhibition by New Quinazoline-Isatin Hybrids: Design, Synthesis, Biological Evaluation and Mechanistic Studies. [PDF]

Pharmaceuticals (Basel)
Alanazi MM, Al-Wabli RI.
europepmc   +1 more source

Human Fecal Transplantation Modifies the Gut Microbiota but Not Metabolites in Colon Cancer Patient-Derived Xenografts. [PDF]

Int J Mol Sci
Unrug-Bielawska K, Sandowska-Markiewicz Z, Kaniuga E, Cybulska-Lubak M, Borowa-Chmielak M, Czarnowski P, Piątkowska M, Bałabas A, Goryca K, Zeber-Lubecka N, Kulecka M, Dąbrowska M, Surynt P, Statkiewicz M, Rumieńczyk I, Mikula M, Ostrowski J.   +16 more
europepmc   +1 more source

Loading of Dicarboxylatoplatinum(II)-NHC Complexes in Bacterial Ghosts as an Advanced Development in Cancer Therapy. [PDF]

Arch Pharm (Weinheim)
Scherfler A, Wurst K, Schwaiger S, Baschieri F, Hermann M, Baecker D, Pashkunova-Martic I, Kircher B, Varbanov HP.   +8 more
europepmc   +1 more source

The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancer. [PDF]

Oncologist
Samalin E, Senellart H, Thezenas S, Jacquot S, Ellis S, Akouz FK, Fiess C, Ramdani M, Portales F, Assenat E, Ychou M, Mineur L, Mazard T.   +12 more
europepmc   +1 more source